NCT04007744: Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

NCT04007744
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible if they have tumors that are MSI-H or have mismatch repair deficiency; Breast cancer patients are only eligible for dose escalation phase (Part A)
Exclusions: Patients with central nervous system metastases that are untreated, symptomatic, or require steroids- see trial for details
https://ClinicalTrials.gov/show/NCT04007744

Comments are closed.

Up ↑